HIV/AIDS

Featured Article
Utilizing Viral RNA Measurements in Patients With HIV
Jenn Zerbato, PhD, post-doctoral research fellow, Peter Doherty Institute for Infection and Immunity, breaks down why HIV RNA could serve as a better measure of efficient latency reversal in both pre-clinical and clinical assessment of latency reversing agents.
Cost-Effective Treatment Option for Multidrug-Resistant HIV-1
Conducted by researchers from RTI Health Solutions and Georgetown University, the analysis considered the cost-effectiveness and budget impact of using ibalizumab, a first-in-class, long-acting,…
Economic Evaluations of STI Control Programs Take Narrow Focus
“The review demonstrated heterogeneity in approaches to evaluate costs and outcomes for STI/HIV control programs,” researchers wrote.

Newsfeed

Utilizing Viral RNA Measurements in Patients With HIV
Cost-Effective Treatment Option for Multidrug-Resistant HIV-1
Economic Evaluations of STI Control Programs Take Narrow Focus
Costs of HIV PrEP Could Curb Expansion, Researchers Warn
HIV/AIDS Costliest Chronic Condition Cluster in US Analysis
Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
HHS Improves HIV/AIDS Care, Support, Access With More Than $2 Billion in Grants
Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection
View More

Insights

Utilizing Viral RNA Measurements in Patients With HIV
Jenn Zerbato, PhD, post-doctoral research fellow, Peter Doherty Institute for Infection and Immunity, breaks down why HIV RNA could serve as a better measure of efficient latency reversal in both pre-clinical and clinical assessment of latency…
Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational…
Addressing Treatment and Prevention of HIV
While great strides have been made in treating people with HIV over the past few decades, the US Preventive Task Force is strongly recommending PrEP for anyone at risk to help prevent the spread of the disease with which approximately 1.1 million…
Generics for HIV: Complex Barriers Impede the Uptake
A number of barriers are keeping patients from gaining access to cheaper, generic versions of HIV treatment medications.
View More

Interactive Features

Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to provide…
View More
Back to Top